Calcimedica, INC Schedule 13G passive stakes

Woodline Partners LP has reported an increase in its beneficial ownership of CalciMedica, Inc. common stock to 8.1%, acquiring 2,489,729 shares.

Armistice Capital, LLC, through its Master Fund, has acquired a 9.99% stake in CalciMedica, Inc., reporting beneficial ownership of 3,411,361 shares.

CVI Investments, Inc. and Heights Capital Management, Inc. jointly file Schedule 13G, reporting beneficial ownership of 5.1% of CalciMedica, Inc. common stock.

Avenue Venture Opportunities Fund II has amended its loan agreement with CalciMedica, maintaining a 4.99% ownership blocker.

Jorey Chernett has filed an amendment to Schedule 13G confirming the complete divestment of all shares in CalciMedica, Inc.

Soleus Capital and affiliated entities report a 2.4% beneficial ownership stake in CalciMedica, Inc. through warrant holdings.

Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and James E. Flynn jointly reported beneficial ownership of 4.34% of CalciMedica Inc.'s common stock, primarily through warrants.

Jorey Chernett has reported beneficial ownership of 7.88% of CalciMedica, Inc.'s common stock as of November 24, 2025.

Soleus Capital Management and affiliated entities disclose a combined 7.5% beneficial ownership in CalciMedica, Inc., including exercisable warrants.

Bering Partners II, L.P. and its affiliates have reported a 5.8% beneficial ownership stake in CalciMedica, Inc., totaling 663,246 shares.

Avenue Capital entities disclose an 8.87% beneficial ownership stake in CalciMedica, Inc., including convertible loans and warrants, while noting a delay in further loan tranche funding.

Avenue Capital Group entities and Marc Lasry have disclosed a combined 8.87% beneficial ownership stake in CalciMedica, Inc., primarily through convertible debt and warrants.

Alafi Capital Company, LLC and Christopher D. Alafi report beneficial ownership of 11.3% of CalciMedica, Inc.'s common stock as of July 22, 2025.

Avenue Venture Opportunities Fund II, L.P. and its affiliated entities, including Marc Lasry, have disclosed a 6.7% beneficial ownership stake in CalciMedica, Inc., primarily through convertible loans and warrants.

Stonepine Capital Management, LLC and its affiliates have filed an amended Schedule 13G, disclosing a 4.6% beneficial ownership stake in CalciMedica, Inc.'s common stock as of March 31, 2025.

Alafi Capital Company, LLC and Christopher D. Alafi have jointly disclosed a 9.6% beneficial ownership stake in CalciMedica, Inc., totaling 1,295,678 shares of common stock, as reported in a recent Schedule 13G filing.

Aisling Capital entities, including Aisling Capital V, LP, have filed an amendment to their Schedule 13G, indicating their beneficial ownership in CalciMedica, Inc. has decreased to 3.9% of common stock.

Revelation Healthcare Fund I and its affiliated entities have reported a complete divestment of their beneficial ownership in CalciMedica, Inc., holding 0.0% of the common stock as of December 31, 2024.